Richter BioLogics Unveils new Biopharmaceutical Facility
Richter BioLogics GmbH & Co KG, the microbial biologics arm of Gedeon Richter Plc has opened a brand new biopharmaceutical cGMP facility in Bovenau, Schleswig-Holstein, Germany.
This opening was celebrated with an official inauguration ceremony on September 13th, attended by senior Richer Group figures and local political representatives.
From the Gedeon Richter Group there was Erik Bogsch, Lifetime Honorary Chairman, Dale Martin a Member of the Supervisory Board, Dr Erik Bogsch the Head of the Biotechnology Business Unit, Dr Kai Pohlmeyer and Johannes Salzbrunn, CEO and COO respectively of Richter Biologics.
Local authorities included the Minister-President of Schleswig-Holstein Daniel Günther and Daniel Ambrock, mayor of Bovenau.
Featuring a market supply of protein and plasmid DNA-based products, in addition to advanced technology to facilitate clinical and large-scale commercial drug production, this plant will be a research & development powerhouse.
It’s set to significantly impact both the economic development of Bovenau and innovation in the field of pharmaceutical manufacturing.
The next Bovenau facility
Richter BioLogics established its first site in Bovenau in 2000, and since then, the facility has developed significantly.
GMP compliant, it has over 125 employees, boasts a litre fermenter volume of 1500 and focuses on microbial production and clinical/commercial supply.
The new Bovenau GMP facility expands on all this, with new 300L and 1500L production lines with enhanced flexibility to manufacture varying products in batches of up to 120 per year.
It features a total manufacturing area of around 10,000 sq metres, with large warehousing facilities, laboratories for exploratory testing and technical areas to optimise product and people flow.
By the end of 2024, it is estimated the facility will help double the number of highly skilled local employees to more than 400.
“This investment demonstrates a strong commitment to the future of Richter BioLogics, to innovation and to GMP manufacturing of biopharmaceuticals made in Germany and to Richter’s commitment to biological products,” says Dr. Erik Bogsch, Head of the Biotechnology Business Unit of Gedeon Richter.
“This new facility together with our existing facilities in Hungary provides for a fully integrated R&D and manufacturing biologics capability, allowing for further access to such medicines to patients worldwide.”
Gedeon Richter Plc: a pharmaceutical leader
Richter BioLogics is one influential strand of the broader Gedeon Richter Plc, an innovation-driven speciality pharmaceutical company that has been changing the landscape of medicine since 1901.
A Hungarian company, Gedeon Richter Plc has 11,603 employees and is present in over 50 countries.
A vertically integrated operation, the multinational company handles pharmaceutical manufacturing, development, research, marketing and sales, helping the global public defeat illness and improve quality of life and health outcomes.
Gedeon Richter Plc has since 2018 been guided by a business strategy to become a prominent player in the league of European pharmaceutical companies.
This latest expansion from its affiliate Richter BioLogics will assist in this endeavour, driving further growth throughout Europe.
“Putting the plant into operation represents a major milestone in the implementation of Richter BioLogics' growth strategy," says Dr. Kai Pohlmeyer, Managing Director at Richter BioLogics.
"With one of Richter’s largest investments in the last decade, we have positioned ourselves as a key player in meeting global market demand and supplying the global pharmaceutical industry with the highest quality biopharmaceutical products. We also increase our flexibility, one of our biggest and most valued strengths."
******
Make sure you check out the latest edition of Manufacturing Digital and also sign up to our global conference series - Procurement & Supply Chain 2024 & Sustainability LIVE 2024
******
Manufacturing Digital is a BizClik brand.
